{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:59:11Z","timestamp":1760151551844,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274006"],"award-info":[{"award-number":["82274006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["DUT21LK11"],"award-info":[{"award-number":["DUT21LK11"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.tiv.2023.105664","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T03:25:17Z","timestamp":1692329117000},"page":"105664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases"],"prefix":"10.1016","volume":"92","author":[{"given":"Weiyi","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2023.105664_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.tiv.2017.11.016","article-title":"In vitro to in vivo extrapolation for high throughput prioritization and decision making","volume":"47","author":"Bell","year":"2018","journal-title":"Toxicol. in Vitro"},{"issue":"27","key":"10.1016\/j.tiv.2023.105664_bb0010","doi-asserted-by":"crossref","first-page":"17960","DOI":"10.1016\/S0021-9258(17)32403-1","article-title":"Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man","volume":"269","author":"Bosma","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.tiv.2023.105664_bb0015","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study","volume":"49","author":"Bruix","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"19","key":"10.1016\/j.tiv.2023.105664_bb0020","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia Chromosome\u2013Positive Leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.tiv.2023.105664_bb0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2014.126","article-title":"Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications","volume":"96","author":"Guillemette","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.tiv.2023.105664_bb0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/jcph.1990","article-title":"Population pharmacokinetics of ponatinib in healthy adult volunteers and patients with hematologic malignancies and model-informed dose selection for pediatric development","volume":"62","author":"Hanley","year":"2022","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.tiv.2023.105664_bb0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2003.02041.x","article-title":"Database analyses for the prediction of in vivo drug-drug interactions from in vitro data","volume":"57","author":"Ito","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"24","key":"10.1016\/j.tiv.2023.105664_bb0040","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.tiv.2023.105664_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"Kiang","year":"2005","journal-title":"Pharmacol. Ther."},{"issue":"34","key":"10.1016\/j.tiv.2023.105664_bb0050","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tiv.2023.105664_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review","author":"Kumar","year":"2022","journal-title":"Mol. Cell. Biochem."},{"issue":"11","key":"10.1016\/j.tiv.2023.105664_bb0060","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/ptr.5697","article-title":"The inhibition of UDP-glucuronosyltransferase (UGT) isoforms by praeruptorin a and B: inhibition of UGTs by PA and PB","volume":"30","author":"Liu","year":"2016","journal-title":"Phytother. Res."},{"issue":"1","key":"10.1016\/j.tiv.2023.105664_bb0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.109.029660","article-title":"Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.tiv.2023.105664_bb0070","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/carcin\/22.7.1087","article-title":"N-Glucuronidation of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) and N-hydroxy-PhIP by specific human UDP-glucuronosyltransferases","volume":"22","author":"Malfatti","year":"2001","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.tiv.2023.105664_bb0075","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1152\/physrev.00058.2017","article-title":"The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms","volume":"99","author":"Meech","year":"2019","journal-title":"Physiol. Rev."},{"issue":"21","key":"10.1016\/j.tiv.2023.105664_bb0080","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1200\/JCO.2007.11.6210","article-title":"Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101","volume":"25","author":"Miller","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.tiv.2023.105664_bb0085","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jcph.109","article-title":"Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects: the journal of clinical pharmacology","volume":"53","author":"Narasimhan","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.tiv.2023.105664_bb0090","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-015-0237-3","article-title":"Sorafenib treatment in child-Pugh a and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors","volume":"33","author":"Ogasawara","year":"2015","journal-title":"Investig. New Drugs"},{"issue":"11","key":"10.1016\/j.tiv.2023.105664_bb0095","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0090-9556(24)15084-2","article-title":"O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9","volume":"28","author":"Ren","year":"2000","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.tiv.2023.105664_bb0100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo drug metabolism in human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.tiv.2023.105664_bb0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12156-011-0072-5","article-title":"Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans","volume":"5","author":"Scholler","year":"2011","journal-title":"Oncol. Rev."},{"issue":"9","key":"10.1016\/j.tiv.2023.105664_bb0110","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","article-title":"The novel BCR-ABL and FLT3 inhibitor Ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2","volume":"11","author":"Sen","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"10.1016\/j.tiv.2023.105664_bb0115","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-12-3214","article-title":"Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute organ dysfunction working group study","volume":"19","author":"Shibata","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tiv.2023.105664_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062543","article-title":"The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study","volume":"8","author":"Stebbing","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.tiv.2023.105664_bb0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1742-7843.2008.00247.x","article-title":"Effect of D256N and Y483D on propofol glucuronidation by human uridine 5\u2032-diphosphate glucuronosyltransferase (UGT1A9)","volume":"103","author":"Takahashi","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.tiv.2023.105664_bb0130","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/cpt.1435","article-title":"Clinical studies on drug\u2013drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation","volume":"105","author":"Tornio","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.tiv.2023.105664_bb0135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.tiv.2023.105664_bb0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/dmd.105.007369","article-title":"Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) \u201cprobes\u201d for human UDP-glucuronosyltransferases","volume":"34","author":"Uchaipichat","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2023.105664_bb0145","article-title":"Clinical drug interaction studies\u2014study design, data analysis, and clinical implications guidance for industry","volume":"32","author":"USFDA","year":"2017","journal-title":"Data Anal."},{"key":"10.1016\/j.tiv.2023.105664_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115595","article-title":"Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase","volume":"424","author":"Wang","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"10.1016\/j.tiv.2023.105664_bb0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/bdd.2241","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug\u2013drug interactions","volume":"41","author":"Wang","year":"2020","journal-title":"Biopharm. Drug Dispos."},{"issue":"21","key":"10.1016\/j.tiv.2023.105664_bb0160","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.V118.21.2745.2745","article-title":"ATP dependent efflux transporters ABCB1 and ABCG2 are unlikely to impact the efficacy, or mediate resistance to the tyrosine kinase inhibitor","volume":"118","author":"White","year":"2011","journal-title":"Ponatinib. Blood"},{"issue":"3","key":"10.1016\/j.tiv.2023.105664_bb0165","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-017-3240-x","article-title":"Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans","volume":"79","author":"Ye","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.tiv.2023.105664_bb0170","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/dmd.30.4.397","article-title":"Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues","volume":"30","author":"Zheng","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.tiv.2023.105664_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the pan-BCR-ABL inhibitor Ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance: structural mechanism of Ponatinib","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"issue":"6","key":"10.1016\/j.tiv.2023.105664_bb0180","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-12-3041","article-title":"Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study","volume":"19","author":"Zhu","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233323001133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233323001133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:44:50Z","timestamp":1760136290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233323001133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":36,"alternative-id":["S0887233323001133"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2023.105664","relation":{},"ISSN":["0887-2333"],"issn-type":[{"type":"print","value":"0887-2333"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2023.105664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105664"}}